Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. (Q54547841)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. |
scientific article |
Statements
Multicenter, phase II, nonrandomized study of docetaxel plus trastuzumab every 21 days as the primary therapy in metastatic breast cancer overexpressing HER2. (English)
1 reference
Sonia Servitja
1 reference
Manuel Ramos
1 reference
Miguel Gil
1 reference
Pedro Sánchez-Rovira
1 reference
Sergio Vázquez-Estevez
1 reference
José Antonio Virizuela
1 reference
Laura García-Estevez
1 reference
Amalia Velasco
1 reference
Ignacio Tusquets
1 reference
1 February 2012
1 reference
23
1 reference
2
1 reference
239-246
1 reference
Identifiers
1 reference